
An experimental vaccine that can treat a common childhood illness called respiratory syncytial virus (RSV) has been developed by researchers in the United States.
There is currently no vaccine on the market for RSV, which is the world's second-leading killer of babies aged one month to one year, after malaria.
Advertisement
RSV causes inflammation in the small airways of the lungs and is the most common cause of pneumonia in babies and of hospitalization of children under five.
?Many common diseases of childhood are now vaccine-preventable, but a vaccine against RSV infection has eluded us for decades,? said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.
?This work marks a major step forward," he said, citing promising animal studies that showed a wide-ranging protective effect.
Planning is under way for human trials of the vaccine.
The research on the vaccine and its structure-based design is described in the journal Science.
Source: AFP
Advertisement
?This work marks a major step forward," he said, citing promising animal studies that showed a wide-ranging protective effect.
Planning is under way for human trials of the vaccine.
The research on the vaccine and its structure-based design is described in the journal Science.
Source: AFP
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Research News

Autoimmune disorders were found to be linked to Sjogren's, systemic lupus erythematosus, and systemic sclerosis.

Successful brain pacemaker implantation has helped a 51year old Parkinson's disease patient to revitalize her quality of life.

Recent recommendations on lifestyle behaviors to prevent progression of rheumatic and musculoskeletal diseases revealed.

The study offers insights into how psoriasis can trigger diabetes, heart disease, and inflammatory bowel disease.

Utilizing microparticles for therapy could mark a significant milestone in the fight against multiple sclerosis (MS) and other autoimmune diseases.